1203505-83-2

Upstream product

• 15964-81-5 methyl 3-hydroxy-4-methoxyphenylacetate 
• 1131-94-8 homoisovanillic acid 
• 1203503-64-3 {3-[2-tert-butylsulfanylmethyl-4-(2,2-dimethyl-propionylamino)-phenoxy]-4-methoxy-phenyl}-acetic acid 
• 1313757-49-1 methyl 2-(3-(2-bromomethyl-4-nitrophenoxy)-4-methoxyphenyl)acetate 
• 1313757-50-4 methyl 2-(3-(2-(tert-butylthiomethyl)-4-nitrophenoxy)-4-methoxyphenyl)acetate 
• 1313757-51-5 methyl 2-(3-(4-amino-2-(tert-butylthiomethyl)phenoxy)-4-methoxyphenyl)acetate 
• 1313757-47-9 methyl 2-(3-(2-formyl-4-nitrophenoxy)-4-methoxyphenyl)acetate 
• 1313757-48-0 methyl 2-(3-(2-hydroxymethyl-4-nitrophenoxy)-4-methoxyphenyl)acetate 

Relevant academic research and scientific papers

DP2 ANTAGONIST AND USES THEREOF

Described herein is the DP2 anatgonist 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl- propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2/

ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.